What FDA's Leucovorin Decision Means for Pharma Developers

On March 10, 2026, FDA approved Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency, marking the first approved treatment for cerebral folate deficiency in patients confirmed to carry a variant in the folate receptor 1 gene.¹ For pharmaceutical developers working in rare and ultra-rare disease spaces, the decision is worth examining, as it was granted without a randomized controlled trial.

Cerebral folate deficiency caused by this specific genetic variant produces severe neurological consequences, including developmental delays, movement disorders, and seizures.¹ Until now, no approved treatment existed. The agency based its decision on a systematic review of published literature, incorporating patient-level case reports and mechanistic data rather than prospectively generated clinical trial evidence.

Tracy Beth Hoeg, acting director, Center for Drug Evaluation and Research, described the broader significance of that approach, in a press release,¹ "It also provides a good example of how observational or 'real world' evidence can lead to an FDA approval when the product is shown to provide clear clinical benefit compared with what is seen with the natural history of the disease."

That statement carries weight for development teams evaluating evidence strategies for small, genetically defined patient populations where enrolling adequate trial numbers is often impractical.¹ The agency has signaled, at least in this instance, that a well-constructed body of real-world and mechanistic evidence can clear the regulatory bar when the treatment effect is large enough relative to the natural disease course.

What Are the Manufacturing Implications?

The agency worked directly with GSK, the new drug application holder, to update the product labeling, incorporating the scientific information necessary for safe and effective use across the newly approved population.¹ The process required coordination on how clinical benefit, patient selection criteria, and safety information would be characterized in the final label.

The manufacturing side of this approval carries its own operational dimension.¹ Elevated off-label prescribing in the months preceding formal approval, driven by public discussion of leucovorin as a potential therapy for autism-related symptoms more broadly, had already put pressure on supply. Regulators have actively encouraged existing manufacturers to increase production capacity to meet demand from the newly defined patient population.

FDA Commissioner Marty Makary noted, in the press release, the treatment,¹ "may benefit some individuals with FOLR1-related cerebral folate transport deficiency who have developmental delays with autistic features.”

Hoeg reinforced the evidentiary discipline behind that boundary, the approval,¹ "demonstrates the FDA's commitment to rapidly identifying effective treatments for ultra rare diseases while maintaining the same evidentiary standards for approval."

For the FDA, speed and rigor are not being positioned as opposing forces.¹ The agency moved from a broad literature review to a targeted approval in a defined genetic population, using real-world evidence as its foundation, and it did so while holding to its standard evidentiary threshold. That precedent is relevant to any team building a regulatory strategy around a rare condition with limited prospective trial data but a meaningful and measurable treatment signal in the published record.

What Are the FDA’s Other Recent Priorities?

The leucovorin approval arrives alongside a separate but thematically connected regulatory shift.² On March 9, 2026, the FDA issued new draft guidance recommending the elimination of certain clinical pharmacokinetic testing requirements in biosimilar development where scientific justification supports doing so. The change could reduce study costs for biosimilar developers by up to 50%, or approximately $20 million per program. It follows an October move reducing unnecessary comparative efficacy studies. Both decisions point in the same direction: the agency is actively reconsidering where resource-intensive requirements are scientifically warranted.

References

1. U.S. Food and Drug Administration. FDA approves first treatment for patients with cerebral folate transport deficiency. News release. March 10, 2026. Accessed March 10, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-cerebral-folate-transport-deficiency
2. U.S. Food and Drug Administration. FDA takes further steps to streamline biosimilar development and make medicines more affordable. News release. October 28, 2025. Accessed March 10, 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable